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Minneapolis, MN, USAAcute kidney injury, defined by a rapid deterioration of renal
function, is a common complication in hospitalized patients.
Among the recent therapeutic options, the use of extracellular
vesicles (EVs) is considered a promising strategy. Here we pro-
pose a possible therapeutic use of renal-derived EVs isolated
from normal urine (urine-derived EVs [uEVs]) in a murine
model of acute injury generated by glycerol injection. uEVs
accelerated renal recovery, stimulating tubular cell prolifera-
tion, reducing the expression of inflammatory and injury
markers, and restoring endogenous Klotho loss. When intrave-
nously injected, labeled uEVs localized within injured kidneys
and transferred their microRNA cargo. Moreover, uEVs con-
tained the reno-protective Klotho molecule. Murine uEVs
derived from Klotho null mice lost the reno-protective effect
observed using murine EVs from wild-type mice. This was re-
gained when Klotho-negative murine uEVs were reconstituted
with recombinant Klotho. Similarly, ineffective fibroblast EVs
acquired reno-protection when engineered with human recom-
binant Klotho. Our results reveal a novel potential use of uEVs
as a new therapeutic strategy for acute kidney injury, high-
lighting the presence and role of the reno-protective factor Klo-
tho.Received 21 June 2019; accepted 7 November 2019;
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Acute kidney injury (AKI), a common complication in hospitalized
patients, is characterized by a rapid deterioration of renal function.1
Around 8%–16% of the patients suffering from AKI are estimated
to progress to chronic renal disease, with high mortality risk and
related costs.2–4 Although the renal tissue shows an intrinsic ability
to regenerate after damage, full recovery in most of the cases is not
achieved. Therefore, multiple clinical approaches for renal regenera-
tion are nowadays being considered.
Among the new therapeutic options for AKI, the use of stem cell-
derived extracellular vesicles (EVs) is gaining increasing interest.5
For example, EVs from mesenchymal stromal cells (MSC EVs)
have been found to exert a promising therapeutic effect.6–12 MSC490 Molecular Therapy Vol. 28 No 2 February 2020 ª 2020 The Author
This is an open access article under the CC BY-NC-ND license (httpEVs may act through multiple regenerative processes, including
induction of tubular cell survival, proliferation, suppression of
inflammation, and inhibition of fibrosis.7–9,13 The transfer of EV bio-
logical cargo (proteins, RNAs, and DNAs) into target cells appears
fundamental in cell fate modulation.14–16 Interestingly, microRNAs
(miRNAs), transferred by MSC EVs, have been considered the
main effectors in the enhancement of proliferation and survival of
renal tubular cells.9,14
Renal cells lining the nephron also release bioactive EVs able to
target downstream cells, suggesting the presence of an intra-
nephron communication between cells along the urinary
lumen.17,18 EVs released by proximal tubular cells were shown to
be internalized by distal tubule and collecting duct cells
in vitro.19 Moreover, in collecting duct cells, the functional transfer
of AQP2 via EVs has been reported.20 Urine-derived EVs
(uEVs) have been extensively characterized for their cargo21–24
and found to contain kidney cell-specific markers from different
nephron segments, such as megalin, cubilin, aminopeptidase, aqua-
porin-1 (AQP1), aquaporin-2 (AQP2), podocin, and podocalyxin
(PDX).25 Indeed, EVs, present in the urine, are considered to
mainly derive from renal cells rather than serum, considering the
small size (6-nm diameter) of renal filtration pore.26 However,
the potential role of uEVs in renal recovery after damage is
currently unknown. Interestingly, a proteomic analysis revealed
that uEVs contain Klotho,21,22 a single-pass transmembrane pro-
tein crucial in renal tissue regeneration.27 Klotho was initially iden-
tified as an anti-aging gene,28 highly expressed in the kidney.29 The
protein’s extracellular domain, when cleaved, is released into the
circulation and acts as a soluble factor, exerting a reno-protective
role in tissue regeneration.30–34 Klotho is modulated within renals.
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. EV Characterization
(A) NanoSight representative images of uEVs isolated by ultracentrifuge (uEV) and floating (uEV float) protocols and of MSC EVs. (B) Representative western blot showing
renal and exosomal markers AQP1, AQP2, Klotho, CD63, and calreticulin in uEVs, uEVs float, and MSC EVs; calreticulin expression by fibroblast cells was analyzed as
positive control. Three different uEV preparations were analyzed with similar results. (C) Representative micrographs of transmission electron microscopy obtained from
purified uEVs (scale bars: right panel, 50 nm; left panel, 200 nm). (D) Representative cytofluorimetric analyses of uEVs showing the positive expression of renal and exosomal
markers AQP1, AQP2, PDX, CD24, CD81, CD63, and the negative expression of monocyte, platelet, and endothelial markers CD45, CD42b, and VEGFR2 (VR2),
respectively. Dotted line histograms specify isotypic controls. Three different uEV preparations were analyzed with similar results.
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in acute31 and chronic damage.32,33 On the other side, forced
expression of exogenous Klotho has been shown to exert a reno-
protective role, indicating that Klotho administration can be
considered as a promising approach for kidney repair.34,35
The aim of the present study is to investigate the possible therapeutic
use of human uEVs in the recovery of renal damage in an experi-
mental model of AKI, generated by glycerol injection. Moreover,
the specific role of the reno-therapeutic factor Klotho, present in
EV cargo, is dissected.
RESULTS
Effect of uEVs on the Recovery of AKI
To determine whether uEVs have therapeutic action, the effect of
uEVs was evaluated in a murine model of rhabdomyolysis-induced
AKI.8 This model is characterized by muscle injury and the subse-
quent release of nephrotoxic substances and iron deposition on
renal tissue (Figure S1). uEVs were obtained by ultracentrifugationof urine from healthy volunteers (n = 25 different pools). In
selected experiments, uEVs were further purified by floating on
density gradient (uEV float), to exclude the effect of non-vesicular
contaminants.36 The mean diameter of uEVs and uEVs float was
175.1 ± 69 nm (mode: 149 ± 30 nm) and 160.1 ± 34 nm (mode:
150 ± 28 nm), respectively, as evaluated by NanoSight analysis
(Figure 1A). The identity of the EVs was confirmed by the
expression of CD63 and lack of calreticulin, an endoplasmic retic-
ulum marker (Figure 1B). Moreover, transmission electron micro-
scopy of uEVs demonstrated their spheroid morphology and
confirmed their size in the nano-range (Figure 1C). EVs from urine
expressed the characteristic renal markers AQP1, AQP2, and
Klotho, absent in MSC EVs used as a control (Figure 1B). More-
over, cytofluorimetric analyses of uEVs confirmed the presence
of renal tubular and podocyte surface markers (AQP1, AQP2,
and PDX), as well as of renal exosomal markers (CD24,37 CD81,
and CD63). No detection of markers of platelets, endothelial
cells, and monocytes/leukocytes, reported in serum EVs,38 was
observed (Figure 1D).Molecular Therapy Vol. 28 No 2 February 2020 491
Figure 2. uEVs Improve Renal Recovery in an AKI Mouse Model
(A) Alterations in renal function were assessed by evaluating creatinine and BUN
levels at day 3 after damage. Mice treated with uEVs (at least five different pools),
isolated by both ultracentrifuge (uEV) and floating (uEV float) protocols, showed
significantly reduced levels of creatinine and BUN compared with untreated AKI
mice (vehicle). Similar amelioration was observed in mice treated with MSC EVs.
No renal function improvement was observed using fibroblast EVs (FIBRO EVs).
Data are expressed as the mean ± SEM of eight mice per group. ANOVA with
Dunnett’s multicomparison test was performed: *p < 0.05 or **p < 0.001 versus
vehicle. (B) Representative micrographs of histological analysis (H&E staining) of
renal tissue from healthy and AKI mice treated with saline (vehicle), uEVs, uEVs float,
MSC EVs, and FIBRO EVs at day 3 after damage. Original magnification 200. (C)
Quantification of tubular hyaline casts and tubular necrosis at day 3 after damage.
Data are expressed as the mean ± SEM. Ten fields per section were analyzed.
ANOVA with Dunnett’s multicomparison test was performed: *p < 0.05 or **p <
0.001 versus vehicle.
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damage, mice received the following treatments: (1) uEVs, (2)
uEVs float, (3) EVs from MSCs, and (4) EVs from fibroblasts.
MSC and fibroblast EVs were used as positive and negative
controls, respectively. All mice received 2.0  108 uEVs/100 mL (a
reported effective dose for MSC EVs14) into the tail vein. The con-
trol group was treated with 100 mL of saline (vehicle). Mice injected
with uEVs and floating uEVs showed a significant reduction of
blood urea nitrogen (BUN) and creatinine at day 3 (48 h after treat-
ment) compared with untreated mice (Figure 2A). The amelioration
in physiological parameters induced by uEVs was similar to that ob-
tained by the administration of pro-regenerative MSC EVs (Fig-
ure 2A). In contrast, fibroblast EVs did not have any effect on the
recovery (Figure 2A).
The histological evaluation of kidney sections in the vehicle group re-
vealed the presence of intra-tubular protein casts and tubular epithe-
lial cell necrosis (Figure 2B). Mice treated with uEVs or MSC EVs, but
not with fibroblast EVs, showed preserved tissue architecture similar
to that of healthy mice (Figure 2B). The number of casts and necrotic
tubules was significantly reduced in uEV- and MSC EV-treated mice,
confirming their beneficial effect (Figure 2C). No significant differ-
ence was observed between animals treated with uEVs and MSCs.
On the same line, uEV and MSC EV treatments improved tubular
cell proliferation (Figures 3A and 3B) and reduced tubular cell
apoptosis (Figure S2) compared with the vehicle group. The pro-
regenerative effect of uEVs was further confirmed by using float
uEVs (Figures 2 and 3).
We further analyzed, at mRNA level, the effect of uEVs on markers
of renal damage and inflammation. In particular, AKI mice showed
an increased expression of renal injury markers such as NGAL,
PAI, and caspase-3 (Figure 3C). Moreover, SOX9, a transcription
factor induced in tubular cells as a consequence of tissue damage,39
was also upregulated (Figure 3C). In contrast, mice treated with
uEVs, as well as MSC EVs, showed a significant downregulation of
injury markers (Figure 3C). In addition, renal tissue from AKI mice
showed a significant increase of pro-inflammatory cytokines such
as tumor necrosis factor alpha (TNF-a), interleukin-1b (IL-1b),
and IL-6 (Figure 3D). The administration of uEVs prevented the in-
flammatory cascade in a manner similar to MSC EVs, with a signifi-
cant reduction of all inflammatory markers analyzed (Figure 3D).
Moreover, the pro-inflammatory driver nuclear factor kB (NF-kB)
was significantly upregulated during AKI and downregulated by
uEV treatment (Figure 3D).
uEV Localization and miRNA Cargo Transfer to Renal Injured
Tissue
To determine the localization of uEVs within injured renal tissue,
uEVs labeled with a fluorescent dye were injected intravenously
and tracked by optical imaging in both healthy and AKI mice.
The biodistribution analysis, performed 4 h after the administration
of uEVs, revealed the presence of fluorescent signal in whole-
body images, as well as in ex vivo isolated kidneys (Figure 4A). The
Figure 3. uEVs Stimulate Tubular Proliferation and Reduce Levels of Renal Injury and Inflammatory Markers
(A) Representative micrographs showing PCNA (Proliferating Cell Nuclear Antigen)-positive cells in kidney tissues from AKI mice injected with saline (vehicle), uEVs, uEVs
float, andMSC EVs at day 3 after damage. Original magnification200. (B) Quantification of PCNA-positive cells in AKI mice treated with saline (vehicle) and EVs at day 3 after
damage. Data are expressed as the mean ± SEM of the count of 10 fields/section (n = 8 mice for each group). ANOVA with Dunnett’s multicomparison test was performed:
*p < 0.05, **p < 0.001 versus vehicle. (C) Histograms showing mRNA expression represented by relative quantification (RQ) of NGAL, PAI, SOX9, and caspase-3 in healthy
and AKI mice, treated with saline (vehicle), uEVs, and MSC EVs, at day 3 after damage. Data are normalized to GAPDH and to 1 for vehicle, and are expressed as the mean ±
SEM of healthy (n = 3), vehicle, and EVs (n = 7/group). One-way ANOVA was performed: *p < 0.05 and **p < 0.001 versus vehicle. (D) Histograms showing the mRNA
expression represented by relative quantification (RQ) of inflammatory markers TNF-a, IL-1b, IL-6, and NF-kB in healthy and AKI mice, treated with saline (vehicle), uEVs, and
MSC EVs, at day 3 after damage. Data are normalized to GAPDH and to 1 for vehicle, and are expressed as the mean ± SEM of healthy (n = 3), vehicle, and EVs (n = 7/group).
One-way ANOVA was performed: *p < 0.05 and **p < 0.001 versus vehicle.
www.moleculartherapy.orgfluorescence, acquired in live animals, was detectable in spleen and
kidney of healthy and AKI mice. However, the injured kidneys
showed higher fluorescent intensity compared with the healthy
ones (Figure 4A). The analysis of dissected kidneys revealed the pref-
erential uEV localization in damaged organs (Figure 4B).
To confirm the effective localization of uEVs into injured kidneys, we
analyzed the transfer of their miRNA cargo to renal tissue. In partic-
ular, from the 204 miRNAs, identified by array within uEVs (Table
S1), we confirmed the expression of the top 10 uEVmiRNAs by quan-
titative real-time PCR, and we evaluated their transfer to renal tissue
(Table S2; Figure 4C). We observed a significant increase of miR-30
family and miR-151 in renal tissue, 4 h after uEV injection, demon-strating the transfer of four uEV miRNAs to injured kidneys (Fig-
ure 4D). Predictive target analysis, using the FunRich tool, performed
on the four highly expressed and transferred uEV miRNAs, showed
1,545 selectively predicted target genes. Subsequently, interactome
network analysis was conducted to identify relevant pathways
involved in uEV biological function (Figure S3). The analysis revealed
a strong representation (p < 0.001) of molecules involved in pro-
regenerative pathways, such as proteoglycan-syndecan signaling
events, insulin growth factor 1 (IGF-1) and hepatocyte growth factor
(HGF). The effect of EV cargo within the renal tissue was further
confirmed by the downregulation of selected miRNA targets. In
fact, SMAD1 and SMAD2, central factors in the interactome, cyclin
D1 (CCND1) (miR-30a target), and c-Myc (miR-30 family andMolecular Therapy Vol. 28 No 2 February 2020 493
Figure 4. Localization of Labeled uEVs and miRNA Cargo Transfer
(A) Representative fluorescence images of healthy and AKI mice injected with DiD and DiD-labeled uEVs (DiD uEV), evaluated 4 h after EV injection. (B) Representative images
of fluorescent dissected kidneys of AKI and healthy mice sacrificed 4 h after EV injection. Quantification of the fluorescence intensity of dissected kidneys treated with DiD
uEVs, derived from healthy and AKI mice, was calculated in ROI (region of interest). Data are expressed as mean of average radiance ± SD (n = 6). Student’s t test was
performed: **p < 0.001, AKI versus healthy. (C) List of the 10 most expressed miRNAs in uEVs. (D) Histograms showing miRNA expression levels in renal tissue 4 h after
vehicle or uEV injection. Data are normalized to RNU6B and to 1 for vehicle and expressed as mean ± SD of relative quantification (RQ) (n = 4/group). (E) Histograms showing
the downregulation of selected miRNA targets (SMAD1, SMAD2, CCND1, and c-Myc), represented by relative quantification (RQ), in healthy and AKI mice, treated with saline
(vehicle) and uEVs, respectively, at day 3 after damage. Data are normalized to GAPDH and to 1 for vehicle and are expressed as the mean ± SEM of healthy (n = 3), vehicle,
and EVs (n = 7/group). One-way ANOVA was performed: *p < 0.05 versus vehicle.
Molecular TherapymiR-151 targets) were downregulated in the renal tissue of uEV-
treated mice (Figure 4E).
uEVs Restore Klotho Levels in Injured Tissue
We then focused our attention on a specific renal factor, Klotho,
involved in tissue regeneration. uEVs were found to contain Klotho,
mainly the short soluble isoform (Figure 5A), at levels of 0.5–10 pg/
2.0  108 EV particles, as determined by ELISA. In addition, Klotho
mRNA was also detected within uEVs (32.05 ± 0.75 cycle threshold
[Ct] value).
The expression of Klotho in renal tissue is known to decrease during
acute and chronic damage.40
On the same line, in our data, renal tissue derived from AKI mice
showed a significant reduction of Klotho at both mRNA and protein494 Molecular Therapy Vol. 28 No 2 February 2020levels, compared with the tissue derived from healthy mice (Figures
5B–5E). Of interest, only uEV treatment, and not MSC EV treatment,
significantly increased murine Klotho mRNA 4 h after injection
(Figure 5B). However, no human Klotho mRNA was detected in
injured renal tissue, excluding mRNA direct transfer. Moreover, the
expression of Klotho protein, lost upon damage, was significantly
restored to normal levels 4 and 48 h after uEV administration (Figures
5C and 5D).
The immunohistochemical analysis confirmed the restoration of
Klotho levels, 48 h after EV injection, and showed the predominant
localization of the protein to distal and proximal tubules (Figure 5E).
We further analyzed the expression of two factors linked with the
pro-regenerative effects of Klotho: CTGF35,41 and a-SMA.41 uEV
treatment inhibited both CTGF and a-SMA upregulation observed
in AKI mice (Figure 5F).
Figure 5. uEVs Restore Klotho Levels upon AKI
(A) Representative western blot showing the presence of Klotho in uEVs, but not in MSC EVs. CD63 was used as a control exosomal marker. (B) Histogram showing the renal
mRNA expression of Klotho represented by relative quantification (RQ) in healthy and AKI mice, treated with saline (vehicle), uEVs, and MSC EVs, and analyzed 4 h post EV
administration. Data are normalized to GAPDH and to 1 for vehicle, and are expressed as the mean ± SEM of healthy, vehicle, and EVs (n = 3/group). Student’s t test was
performed: *p < 0.05 versus vehicle. (C and D) Representative western blot of Klotho expression in kidney tissue from healthy and AKI mice, upon saline (vehicle) and uEV
treatment, at days 1 (C) and 3 (D) after damage (4 and 48 h after EV injection, respectively). Data are expressed as the mean ± SD of the band intensity of n = 5 (healthy group)
and n = 7 (vehicle and uEV groups), normalized to vinculin and to vehicle. One-way ANOVAwas performed: *p < 0.05 versus vehicle. (E) Representative micrographs showing
Klotho expression in kidney tissues of healthy and AKI mice injected with saline (vehicle) and uEVs, at day 3 after damage. Original magnification 200 and 1,000. (F)
Histograms showing themRNA levels of CTGF and a-SMA, represented by relative quantification (RQ) in healthy and AKImice, treated with saline (vehicle) and uEVs. Data are
normalized to GAPDH and to 1 for vehicle, and are expressed as the mean ± SEM of healthy (n = 3), vehicle, and EVs (n = 7/group). One-way ANOVA was performed: *p <
0.05 versus vehicle.
www.moleculartherapy.orgKlotho-Carrying EVs Favor Renal Regeneration
To sustain the role of Klotho present in uEVs and to assess
whether the administration of Klotho carried by EVs may have
an advantage over the use of the recombinant Klotho, we
compared their effect on renal regeneration. Mice were treated
with uEVs (containing Klotho at 1 pg/2.0  108 EV particles) or
human recombinant Klotho at the same quantity (1 pg/mouse).
The administration of recombinant Klotho alone, at variance
with uEVs, did not exert any protective effect in damaged renal tis-
sue, as evaluated by BUN, creatinine, and tissue histology
(Figure 6).
We further confirmed the presence of Klotho in EVs released by
human proximal tubular epithelial cells (HK2) (Figure S4).
Tubular cells are considered the major source of EVs found in
urine.19,20 Of interest, when quantified by ELISA, the amount of
Klotho present in HK2 EVs was at the same range as the one in
uEVs (1–2 pg/2.0  108 EV particles). We then analyzed the effectof HK2 EVs in our AKI model. As expected, HK2-derived EVs
displayed a beneficial effect comparable with uEVs (Figure 6).Indispensable Role of Klotho in the Reno-Protective Effect of
uEVs
To dissect the role of Klotho in the reno-protective effect of uEVs, we
compared the regenerative effect of uEVs isolated from the urine
of wild-type and Klotho null mice. Whereas the effect of wild-type
murine uEVs (muEVs) was superimposable to human uEVs, no effect
was observed using Klotho null muEVs (Figure 7). In particular, Klo-
tho null murine uEVs were completely ineffective in restoring tissue
morphology and renal function (Figure 7). Klotho expression in
muEVs isolated from the urine of Klotho null mice was restored by
engineering EVs with human recombinant Klotho. In order to asso-
ciate the role of Klotho, present in human uEVs, with the regenerative
effect of uEVs, we then treated AKImice with Klotho engineered EVs,
deriving from the urine of Klotho null mice. The number of particlesMolecular Therapy Vol. 28 No 2 February 2020 495
Figure 6. Effect of Klotho-Carrying EVs and
Recombinant Klotho
(A) Creatinine and BUN levels and number of tubular hy-
aline casts and tubular necrosis in AKI mice treated with
saline (vehicle), uEVs, HK2 EVs (n = 6), and recombinant
Klotho (rhKL) (n = 4) at day 3 after damage. Data are ex-
pressed as mean ± SEM; ANOVA with Dunnett’s multi-
comparison test was performed: *p < 0.05 or **p < 0.001
versus vehicle. (B) Representative micrographs of H&E of
renal tissue from AKI mice treated with vehicle, uEVs, HK2
EVs, and recombinant Klotho (rhKL) at day 3 after dam-
age. Original magnification 200.
Molecular Therapyinjected was determined based on the range of Klotho present in hu-
man mEVs (10 pg Klotho/mouse). The results showed that kidney
damage was completely abrogated by the administration of Klotho
engineered uEVs derived from Klotho null mice (Figure 7). Overall,
our data suggest that Klotho present in human uEVs is responsible
for promoting renal regeneration.
Regenerative Effect of Klotho Engineered EVs
To further extend the application of Klotho delivery via EVs for renal
regeneration, we engineered ineffective fibroblast EVs with human re-
combinant Klotho (Figure S5). Klotho engineered fibroblast EVs pro-
moted amelioration of renal function in AKI mice, reducing the levels
of renal retention markers and tissue injury molecules (Figures 8A
and 8B). In addition, histological evaluation of renal sections
confirmed the beneficial effect of Klotho engineered fibroblast EVs
on the maintenance of tissue architecture, with limited presence of
casts and necrotic tubules in respect to fibroblast EV-treated mice
(Figures 8C and 8D). In parallel, Klotho engineered fibroblast EVs
significantly stimulated tubular cell proliferation (Figures 8C and
8D) and restored renal Klotho levels that were lost upon damage (Fig-
ures 8E and 8F). These results suggest a new potential strategy for
renal tissue regeneration by engineering EVs with Klotho.
DISCUSSION
In our study, we evaluated the functional role of EVs obtained from
urine of healthy subjects in renal regeneration, using an experimental
murine model of AKI. Our results highlighted the beneficial effect of
uEVs in AKI, an effect similar to that observed byMSC EVs. In partic-
ular, uEVs accelerated renal recovery, mitigating functional and his-
tological abnormalities, characteristics of AKI, and stimulating
tubular cell proliferation. Moreover, uEV treatment strongly abro-
gated the activation of several pro-inflammatory cytokines upon
damage. Of interest, our study revealed the presence of the reno-pro-
tective factor Klotho within uEVs and the restoration of Klotho levels
in injured tissue after uEV administration. Because EVs present in
urine derive mainly from renal tubular cells, we further demonstrated496 Molecular Therapy Vol. 28 No 2 February 2020the presence of Klotho in HK2 released EVs, as
well as their beneficial effect in our AKI model.
The role of Klotho within uEVs was dissected
by engineering non-effective fibroblast EVs
with human recombinant Klotho. Engineeredfibroblast EVs, when administered in AKI mice, stimulated renal
regeneration. Similarly, uEVs derived from Klotho null mice that
did not exert any reno-protective effect acquired regenerative proper-
ties when engineered with human recombinant Klotho.
The pathogenesis of AKI is complex and involves tubular cell death,
inflammation, and oxidative stress.42 The use of stem cell-derived
EVs, and in particular those released by MSCs, is considered a new
innovative therapeutic strategy for renal regeneration.43–46 However,
the fact that MSC EVs are negative for Klotho suggests that MSC EVs
and uEVs act through different renal regenerative mechanisms.
In our study, we suggest that EVs present in urine may be considered
a new source of pro-regenerative EVs with a renal origin. Urinary EVs
are considered to mainly derive from the epithelial cells along the
nephron,47–49 whereas EVs shed by cultured renal tubular cells
have been described as effective in the recovery of ischemia reperfu-
sion injury.50 We here confirmed the renal origin and pro-regenera-
tive properties of uEVs and by gradient density purification, we
excluded the contribution of other non-vesicular contaminants in
kidney repair.
The therapeutic properties of stem cell-derived EVs have been mainly
attributed to their miRNA cargo.9,51 In the current study, we demon-
strated the preferential localization of labeled uEVs within injured
kidneys, as well as the transfer of their specific miRNA cargo to
damaged tissue. Interactome analysis of transferred uEV miRNA
targets revealed several growth factor pathways, such as IGF-1
and HGF, previously implicated in the regenerative properties of
MSC EVs.9
In addition, our study showed the specific presence of the renal
factor Klotho in uEVs. Klotho, mainly produced in the kidney,52
has been found to be involved in renal homeostasis/physiopathology,
regulating transporter and ion channels.53–55 The soluble form has
been described to exert different anti-inflammatory, anti-apoptotic,
Figure 7. Regenerative Effect of Klotho-Engineered
Murine uEVs
(A) Creatinine and BUN levels and number of tubular hy-
aline casts and tubular necrosis in AKI mice treated with
vehicle, wild-type (muEV, 2.0  108/mouse), Klotho null
murine uEVs (muEV KL/, 2.0 108/mouse) (n = 6), and
Klotho null murine uEVs engineered with human recom-
binant Klotho (muEV KL/ + KLOTHO, 2.2  106/
mouse) at day 3 after damage (n = 3). Data are expressed
as mean ± SEM; ANOVA with Dunnett’s multicomparison
test was performed: *p < 0.05 or **p < 0.001 versus
vehicle. (B) Representative micrographs of H&E of renal
tissue from AKI mice treated with wild-type (muEV), Klo-
tho null murine uEVs (muEV KL/), and Klotho null mu-
rine uEVs engineered with human recombinant Klotho
(muEV KL/ + KLOTHO) at day 3 after damage. Original
magnification 200.
www.moleculartherapy.organti-oxidant, and anti-fibrotic effects in renal tissue.53–59 Upon
acute31 and chronic damage,32,33 Klotho levels have been shown to
decline in blood, urine, and kidney. Administration of soluble Klotho,
in preclinical models of AKI, is able to restore endogenous Klotho
expression.27,58–61 In addition, engineering of MSCs with Klotho re-
sulted in an improvement of their regenerative capacity, increasing
their anti-apoptotic and anti-fibrotic properties.62,63
Similarly, in our model, we found a strong reduction of Klotho
expression in renal tissue of AKI mice, whereas uEV treatment pro-
moted de novo Klotho synthesis, restoring normal Klotho levels.
Moreover, miRNAs present in uEVs and transferred to the renal
tissue may act synergistically on Klotho regulation. For instance,
miR-30a, transferred by uEVs, has been described to be involved in
Klotho upregulation by suppressing the methylation of the pro-
moter.64 In addition, CTGF and a-SMA, molecules involved in
Klotho-related pathways,27,35,41 were significantly downregulated
by uEVs. miR-30a has also been shown to directly target CTGF
in cultured cardiomyocytes and fibroblasts.65 Moreover, miR-30
family and miR-151, transferred to renal tissue by uEV administra-
tion, resulted in the downregulation of SMAD1 and SMAD2, previ-
ously described to be implicated in the progression of kidney dis-
ease.66 In addition, miR-151, a direct inhibitor of the mammalian
target of rapamycin (mTOR) pathway, when transferred by MSC
EVs, has been shown to ameliorate systemic sclerosis.67
The natural origin of EVs, along with their high stability in the circu-
lation, makes them ideal candidates for targeted therapy by efficient
transfer of molecules upon engineering.68 The strategy of engineering
EVs with pro-regenerative molecules is currently gaining an
increasing interest.69 However, the advantages in the use of EVs
engineered with Klotho have not been reported yet. In the present
study, Klotho was loaded onto fibroblast EVs, a Klotho negative EV
source previously described as non-effective in renal repair,70,71 and
the inefficacy of naive EVs in AKI was reverted in parallel with therestoration of its endogenous levels. Moreover, the effect of recombi-
nant Klotho administered alone at a dose comparable with that of
uEVs (1 pg/mouse) did not exert any regenerative effect. This further
underlines the ability of EVs as a delivery system, along with possible
synergistic effects of the EV cargo.
To further confirm the role of Klotho, present in uEVs, and consid-
ering the limitations in obtaining human Klotho negative uEVs, we
tested the efficacy of EVs isolated from urine of Klotho null mice,
naive and following engineering with human Klotho. Interestingly,
the lack of efficacy of Klotho null muEVs was reverted when engi-
neered with human recombinant Klotho and injected at the same
dose of Klotho present in human uEVs. This result suggested that
the amount of Klotho carried by human uEVs is sufficient to exert
its reno-protective effect.
In conclusion, in the present study, we propose an innovative use of
uEVs as a therapeutic strategy for renal regeneration. uEVs from
healthy subjects appear to be a novel source of vesicles with pro-
regenerative properties displaying an effect on Klotho modulation.
uEVs may facilitate intra-nephron communication by transferring
regenerative mediators such as soluble Klotho.
MATERIALS AND METHODS
A detailed description of all methods used is provided in the Supple-
mental Materials and Methods.
Cell Culture
Human bone marrow MSCs were purchased from Lonza (Basel,
Switzerland) and cultured in Mesenchymal Stem Cell Growth
Medium (Lonza), as described previously.8 MSCs were used up to
the seventh passage of culture. Human lung fibroblast cells (line
MRC5 PD19; Sigma-Aldrich, St. Louis, MO, USA) were cultured in
DMEM (Lonza) plus 10% FCS (Lonza) and used up to passage 10.
Human proximal tubular cells were purchased from ATCCMolecular Therapy Vol. 28 No 2 February 2020 497
Figure 8. Regenerative Effect of Klotho-Engineered Fibroblast EVs
(A) Creatinine and BUN levels in AKI mice treated with FIBRO EVs and Klotho-engineered fibroblast EVs (FIBRO EV+KLOTHO) at day 3 after damage (n = 3). Data are
expressed asmean ±SEM; ANOVAwith Dunnett’smulticomparison test was performed: *p < 0.05 or **p < 0.001 versus FIBROEVs. (B) Histograms showing the renal mRNA
expression represented by relative quantification (RQ) of NGAL and PAI in AKI mice treated with FIBRO EVs and Klotho-engineered fibroblast EVs (FIBRO EV+KLOTHO) (n =
3). Data are normalized to GAPDH and to 1 for vehicle and are expressed as the mean ± SEM; Student’s t test was performed: *p < 0.05 or **p < 0.001 versus FIBRO EVs. (C)
Representative micrographs of H&E and PCNA-positive staining of renal tissue from AKI mice treated with FIBRO EVs and Klotho-engineered fibroblast EVs (FIBRO
EV+KLOTHO) at day 3 after damage. Original magnification200. (D) Quantification of tubular hyaline casts, tubular necrosis, and PCNA-positive cells at day 3 after damage
(n = 3). Data are expressed as the mean ± SEM. Ten fields per section were analyzed. Student’s t test was performed: **p < 0.001 versus FIBRO EVs. (E) Representative
micrographs showing Klotho expression in kidney tissues of AKI mice treated with FIBRO EVs and Klotho-engineered fibroblast EVs (FIBRO EV+KLOTHO) at day 3 after
damage. Original magnification 200. (F) Western blot showing Klotho expression in injured kidney tissue treated with FIBRO EVs and Klotho-engineered fibroblast EVs
(FIBRO EV+KLOTHO). Data are expressed as the mean ± SD of band intensity normalized to vinculin and to FIBRO EVs (n = 3). Student’s t test was performed: *p < 0.05
versus FIBRO EVs.
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www.moleculartherapy.org(Manassas, VA, USA) and cultured in DMEM (Lonza) plus 10% FCS
(Lonza).
Isolation of EVs
uEVs were isolated from the second morning urine (200 mL) of
healthy volunteers (n = 14, female/male 1:1; age: 34 ± 5 years), as pre-
viously described.72 Approval from the Review Board of A.O.U. Città
della Salute e della Scienza hospital was obtained (Protocol number:
0021671). Consents from all subjects were obtained. The urine was
first centrifuged at 3,000 rpm for 15 min to pellet cells and debris.
Supernatant was collected and supplemented with protease inhibitor
and NaN3 10 mM (Sigma-Aldrich). After filtration through 0.8- and
0.45-mm filters (Merck Millipore, Billerica, MA, USA), samples were
subdivided in 25-mL ultracentrifugation tubes and underwent
ultracentrifugation (OPTIMA L-100 K Ultracentrifuge, Rotor Type
70-Ti; Beckman Coulter, Brea, CA, USA) at 100,000  g for 1 h at
4C. Pellets were further diluted in physiologic solution and under-
went microfiltration with 0.22-mm and 2-h ultracentrifugation at
100,000  g and 4C. The pellet was then resuspended in DMEM
(Lonza) + 1% DMSO (Sigma-Aldrich) and stored at 80C. EV re-
covery was around 2–5  109 EVs/mL. Single uEV preparations
were combined in pools (three donors per pool) that underwent a sec-
ond ultracentrifugation in order to increase EV yield (n = 25 different
pools). To increase the purity of uEVs, we applied a floating protocol
through a sucrose gradient.36 Five fractions were obtained and the
highest one, containing pure EVs, was used.
Cell-derived EVs were obtained from MSC, HK2, and fibroblast
supernatants, cultured overnight in RPMI deprived of FCS. Following
the removal of cell debris and apoptotic bodies, by centrifugation at
3,000  g for 15 min and microfiltration over a 0.22-mm filter, EVs
were purified by 2-h ultracentrifugation at 100,000  g and 4C.
EVs were resuspended in DMEM (Lonza) plus 1%DMSO (Sigma-Al-
drich) and stored at 80C.
For muEV isolation, urine obtained from 14 wild-type BALB/c and 13
KL/ mice was collected in an Eppendorf tube twice a week over the
course of approximately 8weeks and stored at80C.muEVswere iso-
latedusingExoQuick-TC (SystemBiosciences, PaloAlto, CA,USA), ac-
cording to the manufacturer’s protocol. muEVs were resuspended in
DMEM (Lonza) plus 1% DMSO (Sigma-Aldrich) and stored at
80C.Particle size and concentrationweremeasuredusingNanoSight
NS300 (NanoSight, Amesbury, UK) and analyzed using Nanoparticle
Tracking Analysis software. EV recovery was around 1 109 EVs/mL.
For the engineering of EVs, human Klotho recombinant protein
(R&D System, Minneapolis, MN, USA) was loaded onto EVs using
the Exo-Fect Exosome Transfection Reagent (System Biosciences),
according to the manufacturer’s protocol.
EV Engineering
For the engineering of EVs, Klotho recombinant protein was loaded
onto EVs using the Exo-Fect Exosome Transfection Reagent (System
Biosciences), according to the manufacturer’s protocol. In brief, 5 mgof EVs (quantified by Bradford) was incubated (by mixing) with
2.5 mg of recombinant Klotho in the presence of Exo-Fect solution
for 1 h at +4C. For the blockage of loading reaction, 30 mL of Exo-
Quick-TC was added to the mixture and kept for 30 min on ice. A
pellet of Klotho-loaded EVs was obtained by a further 10 min of
centrifugation at 13,000 rpm.
Western Blot
Ten micrograms of EV-lysates and 50 mg of renal tissue lysates were
loaded on Mini-PROTEAN TGX pre-cast electrophoresis gels (Bio-
Rad, Hercules, CA, USA). Proteins were subsequently transferred on
iBlot nitrocellulose membranes (Invitrogen, Carlsbad, CA, USA) and
blotted with antibodies against Klotho (Abcam, Cambridge, UK), vin-
culin (Sigma-Aldrich), AQP1 (Santa Cruz Biotechnology, Dallas, TX,
USA), AQP2 (Santa Cruz Biotechnology), CD63 (Santa Cruz Biotech-
nology), and calreticulin (Cell Signaling, Danvers, MA, USA). Chemi-
luminescent signal was detected using the ECL substrate (Bio-Rad).
Cytofluorimetric Analysis
Flow cytometric analysis was performed on EVs adsorbed onto sur-
factant-free white aldehyde/sulfate latex beads 4% w/v, 4-mm diam-
eter (Molecular Probes, Carlsbad, CA, USA) using a FACSCalibur
machine (Becton Dickinson, Franklin Lake, NJ, USA). The adsorbed
EVs were analyzed with the following anti-human fluorescent-conju-
gated monoclonal antibodies: PDX-APC (allophycocyanin), CD24-
fluorescein isothiocyanate (FITC), CD63-APC, VEGFR2-(VR2)-
APC, CD81-phycoerythrin (PE), CD45-FITC, and CD42b-FITC.
AQP1 and AQP2 were conjugated to an Alexa Fluor 488 dye through
the Alexa Fluor Antibody Labeling Kit (Molecular Probes). Isotypic
controls FITC-, PE-, or APC-conjugated Mouse IgG1 (all purchased
by Miltenyi, Bergisch-Gladbach, Germany) were used.
Glycerol-Induced Model of AKI
Animal studies were conducted in accordance with the NIH Guide
for the Care and Use of Laboratory Animals (Permit Number: 274/
2015-PR). The in vivo experiments were conducted following the
regulatory standards. As previously described,8 AKI was performed
in 8-week-old FVB mice by intramuscular injection of 8 mL/kg of
50% solution of hypertonic glycerol (Sigma) into inferior hindlimbs.
On day 1 post injury, mice received a tail vein injection of 2.0  108
EVs in 100 mL saline or the same volume of saline (vehicle). The
following EVs were tested: (1) uEVs isolated with ultracentrifuge;
(2) uEVs isolated with floating protocol; (3) MSC EVs isolated with
ultracentrifuge; and (4) EVs released by fibroblasts (n = 8mice/group)
and fibroblast EVs, engineered with human Klotho injected at the
same particle number as uEVs (2.0  108 EVs/mouse) (n = 3). In
addition, HK2 EVs (2.0  108 EVs/mouse) and recombinant Klotho
(1 pg/mouse) (R&D Systems) were also tested (n = 6). Finally, muEVs
(2.0 108 EVs/mouse), muEV KL/ (2.0 108 EVs/mouse) (n = 6),
and muEV KL/ engineered with Klotho (n = 3), injected at the
same amount of Klotho contained in human uEVs (10 pg/mouse;
2.2 106 EVs/mouse), were also used. Mice were sacrificed 48 h after
the EV administration. A selected number of mice (n = 4/group)
treated with uEVs, MSC EVs, and saline were sacrificed 4 h postMolecular Therapy Vol. 28 No 2 February 2020 499
Molecular TherapyEV administration. After sacrifice, blood was recovered for evaluation
of renal functional parameters, and kidneys were stored for histolog-
ical and molecular analyses.
Molecular Analyses
uEV miRNA Content
Total RNA was extracted from a pool of uEVs deriving from 8 L of
urine. uEVs were lysed in TRIzol (Ambion Waltham, MA, USA)
and RNA was extracted using miRNeasy kit (QIAGEN, Hilden, Ger-
many) following the manufacturer’s protocol. Sixty nanograms of
RNA was precipitated and pre-amplified prior to miRNA quantifica-
tion. Expression of 380 different miRNAs was evaluated by quantita-
tive real-time PCR using TaqMan Array MicroRNA card B (v.3.0) ac-
cording to Megaplex protocol. Quantification was performed using a
QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA). Ct values were analyzed by QuantStudio 12K
Flex software (Applied Biosystems) using global normalization. miR-
NAs with raw Ct values higher than 35 were not included in the anal-
ysis.14 For quantitative real-time PCR of uEV miRNAs, first-strand
cDNA was produced from 200 ng of total RNA using the miScript
Reverse Transcription kit (QIAGEN). miRNA expression analysis
was performed using sequence-specific oligonucleotide primers
(MWG-Biotech, Ebersberg, Germany) and the miScript SYBR Green
PCR kit (QIAGEN). Relative quantification of the products was per-
formed using a 96-well StepOne Real-Time System (Applied
Biosystems).
Tissue mRNA Analysis
For the isolation of total RNA from mouse kidneys, pieces of around
50 mg of renal tissue were homogenized in 1 mL of TRIzol Reagent
(Ambion) according to the manufacturer’s protocol. First-strand
cDNAwas produced from 200 ng of total RNA using the High Capac-
ity cDNA Reverse Transcription Kit (Applied Biosystems). For gene
expression analysis, quantitative real-time PCR was performed, in a
20-mL reaction mixture containing 5 ng of cDNA template, the
sequence-specific oligonucleotide primers (MWG-Biotech), and the
Power SYBR Green PCR Master Mix (Applied Biosystems).
mGAPDHwas used as housekeeping normalizer. Fold change expres-
sion with respect to vehicle was calculated for all samples.
ELISA for Klotho
The quantification of Klotho levels within EVs was performed using
an anti-human ELISA (Human soluble a-Klotho code 27998;
Immuno-Biological Laboratories)73 according to the manufacturer’s
protocol. In detail, three pools of uEVs, HK2 EVs, Klotho engineered
fibroblast EVs, and muEV KL/ engineered with Klotho were lysed
in 40 mL of radioimmunopreciptation assay (RIPA) buffer and diluted
(1:1 v/v) in the resuspension buffer provided in the ELISA.
Statistical Analysis
Results are generally expressed as mean ± SD or ± SEM, as indicated.
Statistical analysis was performed by ANOVA with Dunnett’s multi-
comparison test or by Student’s t test when required. A p value <0.05
was considered significant.500 Molecular Therapy Vol. 28 No 2 February 2020SUPPLEMENTAL INFORMATION
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